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As the list of putative driver mutations in glioma
grows, we are just beginning to elucidate the effects
of dysregulated developmental signaling pathways
on the transformation of neural cells. We have em-
ployed a postnatal, mosaic, autochthonous glioma
model that captures the first hours and days of
gliomagenesis in more resolution than conventional
genetically engineered mouse models of cancer.
We provide evidence that disruption of the Nf1-Ras
pathway in the ventricular zone at multiple signaling
nodes uniformly results in rapid neural stem cell
depletion, progenitor hyperproliferation, and glio-
genic lineage restriction. Abolishing Ets subfamily
activity, which is upregulated downstream of Ras,
rescues these phenotypes and blocks glioma initia-
tion. Thus, the Nf1-Ras-Ets axis might be one of the
select molecular pathways that are perturbed for
initiation and maintenance in glioma.INTRODUCTION
High-grade gliomas are among the most fatal primary brain
tumors (Ostrom et al., 2014) and remain difficult to treat, although
recent advances in radiation and chemotherapy have added a
few months of survival, albeit with side effects (Stupp et al.,
2009). Most treated primary gliomas inevitably evolve into sec-
ondary gliomas, which are almost always fatal (Quant et al.,
2010). Understanding the molecular alteration(s) underlying the
initial formation of tumors may determine critical steps required
in the oncogenic process and may thereby lead to targeted
therapies.
Genetically engineered mouse models have been used to
study initiating events in gliomagenesis by utilizing conditional
knockout of tumor suppressors in promoter-defined cell popula-
tions or by viral delivery of oncogenes. Commonly investigated258 Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authorsthemes include the cell(s) of mutation (i.e., cell in which the driver
gene is mutated), the cell(s) of origin (the cancer initiating cell),
and the nature of tumor propagating cells (proliferative cells
contributing to tumor mass, which may not be able to generate
the full repertoire of tumor cells) in glioma (Visvader, 2011). Initial
findings suggested that brain tumor initiating cells display the
properties of neural stem cells (NSCs), including the ability to
self-renew and give rise to multiple daughter cell types (Alcan-
tara Llaguno et al., 2009). Additional studies provided evidence
that oligodendrocyte progenitor cells (OPCs) can directly trans-
form into symmetrically expanding tumor-propagating cells
upon acquisition of driver mutations (Assanah et al., 2006; Canoll
and Goldman, 2008; Lei et al., 2011; Liu et al., 2011; Persson
et al., 2010; Sugiarto et al., 2011). It remains unclear if these
disparate findings reflect methodological differences or intrinsic
differences in tumor types (Chen et al., 2012b; Lei and Canoll,
2011). Nevertheless, the resulting tumors in all of these models
(and in patient tissue) are made up of cells histologically resem-
bling glia (Chen et al., 2012b), suggesting that signaling path-
ways necessary for gliogenesis might be required for glioma
regardless of the cell of origin.
Interestingly, the perinatal switch from neurogenesis to glio-
genesis during development has recently been found to critically
involve the Ras pathway, a pathway intimately linked to glioma
(Cancer Genome Atlas Research Network, 2008). Direct Ras
activating mutations (e.g., Ras G12V) display increased gliogen-
esis (Li et al., 2014). Similarly, inactivating mutations to Nf1—a
Ras inhibitor—and activating Pdgfra mutations are associated
with glial proliferation and glioma (Liu et al., 2011; Paugh et al.,
2013; Wang et al., 2012). Moreover, conditional knockout of
the downstream effectors of Ras—Mek1 andMek2--led to abro-
gated developmental gliogenesis (Li et al., 2012). Furthermore,
this study identified Etv5, a member of the Ets transcription fac-
tor family, as a likely mediator of perinatal gliogenesis (Li et al.,
2012).
To investigate the specification of glial cells during glioma
initiation, we focally targeted the postnatal day 2 ventricular
zone (VZ) by combining electroporation (EP) with piggyBac
transposition. This allows for mosaic genetic modification of
the proliferating NSC and progenitor populations. Specifically,
we hyperactivated the Ras pathway either by EP of Kras or
Hras G12V mutants or by EP of Pdgfra or Erbb2 receptor mu-
tants. Additionally, Raswas disinhibited through Nf1 knockdown
or knockout by directly targeting Nf1 with state-of-the-art miR-E
based short hairpin (sh)RNAs (Fellmann et al., 2013) or using Nf1
floxed mice (Zhu et al., 2001).
The ability of this model to track the transformative events re-
sulting from disparate mutations in VZ cells with fluorescent ge-
netic reporters led to the discovery of common events occurring
during tumorigenesis. Disrupting the Ras pathway in these cells
drives a depletion of NSCs and an emergence of rapidly prolifer-
ating glia that subsequently yield tumors with differing glioma
subtype profiles and pathological grades. We demonstrate that
this Ras-mediated glioblast specification requires increased
Ets activity. Disrupting Ets signaling effectively reduces Ras-
mediated NSC depletion and tumor formation. Taken together,
the Ets family may represent a critical component in stem and
progenitor cell transformation into glia and ultimately the forma-
tion of glioma.
RESULTS
Stable Transgenesis of VZ Cells
To evaluate the ability of transposition to mediate stable trans-
gene expression, plasmids harboring CMV/chicken beta actin
(CAG)-driven EGFP flanked by terminal repeats (PB-TR) that
enable the genomic integration by PBASE (Chen et al., 2012a)
were expressed in the mouse left lateral ventricle using EP at
postnatal day 2 along with an electrode orientation to target
the striatal wall of the left ventricle (Figures 1A and 1B). At
6 months post-EP, a large number of cells showed stable
EGFP expression, while the EP of an episomal plasmid lacking
PB-TR resulted in a 10-fold reduction in the number of stably
fluorescing cells, indicating that PBASE transposition facilitates
stable transgenesis (Figure 1C).
Mousebrainswereanalyzed4hrpost-EP toacutely identify the
electroporated (EP-ed) cells, most of which were radial glia (RG),
a bonafideNSCpopulation (Rakic, 2003), and a small fraction ex-
pressed the progenitor markers ASCL1 and/or OLIG2, but no cell
was both ASCL1+ and OLIG2+ (Figures 1D and 1E). At two days
after EP,many cells remained VIMENTIN+RG, possessing proto-
typical apico-basal polarity and a VZ-anchored cell body with a
basal process >100 mm (Figures 1F–1G4 and S1A). Over six
months, these EP-ed cells collectively gave rise to olfactory
bulb neurons (Figures 1H and 1J), OPCs (Figure 1K, SOX10+/
OLIG2+cellsmorphologically identifiable asmultipolar glia exhib-
iting fewer processes when compared with astrocytes as seen in
Figures S1B–S1B3), oligodendrocytes (Figures 1I [arrows], 1K,
and 1L), astrocytes (Figure 1M; ALDH1L1+/GFAP+ glia with a
dense cloud of processes as displayed in Figures S1C–S1C3),
and ependymal cells (Figure 1N; i.e., VZ-located, apically multici-
liated, cuboidal cells). Some RGs remained in the VZ, demon-
strating their long-term self-renewal or quiescence (Figure 1I).
We did not observe any hyperplasia or tumor formation in trans-
posed EP-ed cells (e.g., containing only the stably inserted
TagBFP2 nuclear reporter or EGFP; Figure 1I; J.J.B., R.L., data
not shown).Tumorigenesis Initiated by EP of Single Oncogenes
To assess the ability of this methodology to generate glioma,
we EP-ed the following constitutively active oncogenes, which
have been identified as driver mutations in previous models
or in patient tumors: Erbb2-V664E, Hras-G12V, Kras-G12V,
and Pdgfra-D842V (Catalogue of Somatic Mutations in Cancer,
2008; Forshew et al., 2009; Janzarik et al., 2007; Ozawa et al.,
2010; Schwartzentruber et al., 2012; Sharma et al., 2005; Ya-
maoka et al., 2000).
Several strategies were employed to unambiguously visu-
alize targeted cells. For Erbb2 plasmids, we co-expressed the
mCLOVER GFP using a self-cleavable 2A peptide sequence
(Figures S2A and S2B). Hras-G12V and Kras-G12V genes were
fused with EGFP (Figure S2A) and Pdgfra-D842V was con-
structed without a reporter or tag (Figure S2A). The control
gene was a fusion of EGFP with the CAAX box found in Hras C
terminus, which results in membrane labeling (Figure S2C).
This membrane-targeted EGFP was also used for visualization
of Pdgfra D842V by co-EP of both plasmids.
Stable expression of Erbb2-V664E or Hras-G12V oncogenes
led to rapid development of hyperplasia between 6 days and
2 weeks (Figures 2A, 2B, S2D, and S2E). Though starting as
small populations of VZ cells, the EGFP+ cells became highly
infiltrative and tumors occupied a significant proportion of
the forebrain by 6 weeks (Figures 2C and S2F). EP of Kras and
Pdgfra mutations also resulted in tumors (Figures S2G–S2J).
Co-expression of oncogenes with a ferritin-expressing plasmid
permitted cell growth to be tracked in live animals using MRI.
Results showed tumor growth 3 weeks post-EP specifically in
the left hemisphere at the EP site (Figures 2D–2F2). Importantly,
wild-type Hras or Erbb2 overexpression did not exhibit notice-
able increases in proliferation or loss of apicobasal polarity (Fig-
ures S2K and S2L). Furthermore, no mice EP-ed with control
plasmids developed tumors, indicating that pBase expression
or random genomic insertions of plasmids are not sufficient to
initiate significant tumorigenesis under these conditions. These
findings show that PBASE-mediated stable integration of a sin-
gle constitutively active Ras pathway mutation in the VZ niche
can initiate tumors.
Hras G12V and Erbb2-CA driven tumors were 100% pene-
trant (Figure 2G). The majority of Hras G12V animals showed
hydrocephalus and doming of the skull and reached terminal
endpoint within 200 days, whereas control animals (i.e.,
EP-ed with membrane EGFP and transposed with PBASE)
did not show any abnormal symptoms or shortened lifespan
(Figures 2G–2I). We observed overgrowth of the left hemi-
sphere, abnormal vascularity, and cortical thinning in tumor-
bearing animals (Figure 2J). The Hras-G12V tumors were
graded by a clinical neuropathologist according to the World
Health Organization criteria and found to possess the hallmarks
of high grade anaplastic glioma by pathology, notably an oligo-
dendroglioma component as demonstrated by the artifactual
‘‘fried egg’’ appearance of tumor cells, necrosis, endothelial
proliferation, calcification, and high cellularity (Figures 2K–2P).
Erbb2-V664E animals exhibited similar pathological features
(Figures S2M–S2R).
All Ras and Erbb2 mutations were pathologically classified
as high grade glioma. However, even littermates—treatedCell Reports 12, 258–271, July 14, 2015 ª2015 The Authors 259
Figure 1. Postnatal EP Combined with PiggyBac Transposition Targets NSCs and Progenitor Cells and Provides Sustained Transgene
Expression
(A) Postnatal EP of the VZ cells with EGFP-expressing plasmid.
(B) PBASE catalyzes the genomic integration of gene of interest (GOI).
(C) Rate of stable expression by PBASE-mediated integration, gene trapping, or episomal plasmid expression. The error bars show ± SEM; n = 3 (*p < 0.05,
**p < 0.01, and paired t test).
(D and E) P2 coronal section taken 4 hr after EP shows mostly RGs and few ASCL1+ and/or OLIG2+ progenitors.
(F–G4) P4 section EP-ed at P2 yields largely VIMENTIN
+ RGs and few non-VZ progenitors (arrowheads).
(H and J–N) Themultipotent VZ cells EP-ed at P2 give rise to (H and J) neurons, (K) immature, and (L)mature oligodendrocytes, (M) astrocytes, and (N)multiciliated
ependymal cells.
(I) 6-month section EP-ed at P2 confirms long-term stable expression.
(The scale bars for A, D, F, H, and I represent 100 mm and the scale bars for G and J–N represent 10 mm).
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Figure 2. Tumor Progression and Pathological Findings in EP-ed Mice
(A–C) Stitched images showing time-series development of Hras tumors.
(D and E) MRI images of 3-week brains co-EP-ed with ferretin plus Hras or EGFP.
(F–F2) Micro-MRI showing ferritin+ tumor in the left hemisphere.
(G) Survival analysis of control, Erbb2 CA, and Hras-G12V EP-ed mice.
(H and I) Hras G12V animal presents a domed skull and hydrocephalus in the left hemisphere (J) at moribundity.
(K–P) Pathological hallmarks of high-grade glioma at moribundity found in Hras tumor.
(The magnification for K, M, N, and O, is 1003 and L and P is 2003).identically—could exhibit divergent pathologies within the grade
III and IV subtypes. Specifically, tumors were diagnosed as
anaplastic astrocytoma, anaplastic oligodendroglioma, ana-
plastic oligoastrocytoma, or glioblastoma multiforme.
Premature RG Depletion and Progenitor Hyperplasia
through Ras Hyperactivation
Employing a counting frame-based system for quantification
(Figures S3A and S3B), we observed that EP-ed VZ cells rapidly
lost their RG morphology and increased proliferation by 6 days
(Figures 3A–3H). This conversion of morphology happened in
all Hras, Pdgfra, and Kras EPs, suggesting that this effect is the
result of the consistent hyperactivation of Ras that is commonly
associated with gliomagenesis (Figures 3G and S2G–S2J). Thismorphological change was significantly correlated with in-
creases in OLIG2 expression, indicating potential lineage restric-
tion (Figures 3I–3O).
We employed SOX10 immunolabeling to investigate oligoden-
drocyte lineage restriction, as it is specific for this class of
cells in the normal brain. From 6 days to 2 weeks, the number
of SOX10+/EGFP+ tumor cells rapidly increased as the tumor
progressed, indicating an increase in OPCs within the growing
tumor (Figures 3P–3V).
The acute changes in expression of oligodendrocyte cell
markers were replicated using cerebral cortex-derived human
neural progenitor cells (hNPCs). hNPCs EP-ed with Hras or
Kras mutants became compact in nature and upregulated
OLIG2 and downregulated the astrocyte lineage marker GFAP,Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authors 261
Figure 3. Somatic Mutation Rapidly Depletes
RG and Expands Tumor Cells
(A–F) P4 and P8 coronal sections of control, Erbb, and
Hras brains stained with V5, EGFP, and KI67.
(F2–F5) Co-localization of KI67, EGFP, and V5 in the
boxed area from (F).
(G and H) Line chart comparing the quantification of
EGFP-positive KI67+ cells and the RGs at 2 days and
6 days after EPs with control (A and D), Hras (C and F),
Erbb (B and E), and WT-Hras (data not shown).
(I–N) P4 and P8 coronal sections of control, Erbb, and
Hras brains stained with V5, EGFP, PDGFRA, and
OLIG2.
(M2–M6) Co-localization of PDGFRA, EGFP, V5, and
OLIG2 in the boxed area from (M).
(O) Line chart comparing the quantification of EGFP-
positive OLIG2+ at 2 days and 6 days after EPs with
control (I and L),Erbb (J andM),Hras (K andN), andWT-
Hras (data not shown).
(P–U) P8 and P16 coronal sections of control, Erbb, and
Hras brains stained with V5, EGFP, and SOX10.
(U2–U5) Co-localization of SOX10, EGFP, and V5 in the
boxed area from (U).
(V) Line chart comparing the quantification of EGFP-
positive Sox10+ at 6 days and 2 weeks after EPs with
control (P and S), Hras (R and U), Erbb (Q and T), and
WT-HRas (data not shown). The error bars show ±
SEM; n = 3 mice (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, and paired t test). (The scale bar repre-
sents 25 mm for A–F, I–N, and P–U).
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Figure 4. Nf1 Loss of Function through Knockdown or Conditional Knockout Shows Significant Reduction in RG and Striatal Gliogenesis
(A) Schematic of Nf1 miR-E knockdown construct.
(B) Strategy for floxed Nf1 mouse targeting by EP of Cre along with a FlEx Cre reporter.
(C–E) WT CD1 brains EP-ed with shLuc, shNf1, and shNf1 plus NF1 cDNA.
(F–H) Nf1fl/fl brains EP-ed with EGFP, Cre, and Cre plus NF1 cDNA.
The white arrows show RG fibers; the red arrowhead shows truncated RG fiber; and the orange arrowhead shows glial clusters.
(I) Histograms showing the relative quantifications of the RGs by morphology in the brains shown by (C)–(E).
(J) Histograms showing the relative quantifications of the RGs by morphology in the brains shown by (C)–(H).
The error bars represent ± SEM; n = 3 mice (*p < 0.05, **p < 0.01, ***p < 0.001, and paired t test). (The scale bar represents 100 mm for C–H).while control hNPCs retained GFAP expression and a spindle
shaped morphology reminiscent of RG in vitro (Figures S3C–
S3F).
Ras hyperactivation often results from the loss of Nf1 activity
that frequently occurs in glioma patients (Dasgupta et al.,
2005; Schwartzentruber et al., 2012). To test whether Nf1 defi-
ciencymirrorsHras phenotypes, we adapted twomethodologies
for use with our EP technique. First, we knocked down Nf1 in
EP-ed cells using the recently reportedmiR-E shRNA technology
(Figure 4A) (Fellmann et al., 2013). In addition, we created a strat-
egy to EP Nf1 floxed mice (Zhu et al., 2001) with a custom-made
FlEx reporter plasmid and Cre (Figure 4B).
In validating miR-E targeting plasmids, western blot analysis
confirmed that all five candidate Nf1 shRNA sequences effi-
ciently knocked down their cognate sensor EGFP in trans-
fected N2a cells more strongly than a previously characterized
shEGFP (Figures S4A and S4B; Matsuda and Cepko, 2007).
Nf1.789 (shNf1) was used in all further experiments because
its effect could be rescued by a codon-optimized human
NF1 cDNA (Stowe et al., 2012; Figures S4C and S4D). When
we EP-ed shNf1 and sensor EGFP, only a few ‘‘escaping’’
EGFP+ RGs remained, whereas a large increase in EGFP stria-
tal cells could be seen in these groups (Figures S4E–S4E4).
Control shRNA against firefly luciferase (luc.1309 heretofore‘‘shLuc’’; Premsrirut et al., 2011) did not decrease sensor
EGFP expression or change the overall distribution of EGFP cells
(Figures S4F–S4F4).
We then EP-ed littermates with shLuc, shNf1, or shNf1 + hu-
man NF1. After 6 days, shLuc control mice retained the stereo-
typical RGs, while shNf1 mice displayed markedly more striatal
glia and a loss of RGs. These shNf1 phenotypes were partially
rescued by co-expressing the human NF1 cDNA (Figures 4C–
4E). Immunostaining for NF1 protein confirmed the resistance
of the human NF1 cDNA (Stowe et al., 2012) to shNf1 after co-
EP of both (Figures S4G–S4G3). Notably, the human NF1 signal
was enriched in VZ cells, but this episomal cDNA appeared to be
rapidly diluted in the escaping, proliferative glial populations (Fig-
ures S4G–S4G3). The RG depletion phenotypes were replicated
in the floxed Nf1 mice EP-ed with Cre recombinase (Figures 4F
and 4G) and the loss of RGs was again attenuated by co-ex-
pressing human NF1 (Figure 4H). Both shNf1-EP-ed and Cre-re-
combinedNf1mice showed a significant reduction in the number
of RGs (Figures 4I and 4J). These data suggest that both Ras
hyperactivation and Nf1 reduction in RG leads to the cell auton-
omous depletion of RGs.
In addition to creating focal, genetic mosaic models for cell
tracing, we used this technology to test if the depletion of
RGs is evidence of a change in neural stem cell potential.Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authors 263
(legend on next page)
264 Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authors
EP-ed plasmids are preferentially taken up by the RGs undergo-
ing M-phase of the cell cycle (Stancik et al., 2010). Because the
VZ cell cycle is roughly 12–18 hr, we hypothesized that we could
electroporate the same animal twice with different plasmids,
8 hr apart, and expect to generate two genetically different
cohorts of RGs (Figure S5A). To mitigate the possibility of
double positive cells, we added Cre recombinase in the first
round of EP to inactivate any floxed-Hras plasmid that might
enter the same cell during the second EP (Figure S5A). After
performing double EP with hemagglutinin (HA)-tagged, nuclear
beta-glucosidase (Bgla; McCutcheon et al., 2010) + Cre in the
first EP (control group) and nuclear TagBFP2 (TagBFP2nls-
V5) + Ollas/FLAG-epitope-tagged Hras G12V in the second
EP (HRas group), we dissociated EP-ed cells from four ani-
mals, grew them in culture with growth factors for 2 days to
permit expansion and clear debris, and then re-plated cells
on coverslips without growth factors to induce differentiation
(Figure S5A). As with our in vivo experiments, a significant in-
crease in OLIG2+ cells was observed in the Hras group (Fig-
ures S5B and S5C). After 7 days, the absolute number of
OLIG2+ cells in the Hras group was almost 17-fold higher
(290 ± 141 OLIG2+ cells in Hras-G12V versus 17 ± 7 OLIG2+
cells in controls; n = 4). Neuronal differentiation was almost
completely abolished in Hras cells, as we found a total
of four doublecortin-positive neuronal cells from 4,505
TagBFP2+/Hras-G12V cells sampled across four cell lines (Fig-
ures S5B and S5D). Astrocytic differentiation was decreased in
Hras-G12V cells (64.8% ± 12.7% compared to 48.6% ±
16.4% GFAP cells; Figures S5B and S5E). In agreement with
the disappearance of olfactory bulb (OB) neurons in vitro, OB
neurogenesis appeared to decrease in vivo in Hras-G12V
and Erbb2 groups (Figures S5F–S5H). These data show that
Hras hyperactivation in NSCs prevents neuronal lineage spec-
ification and favors glial lineage specification. Collectively,
these results suggest that the NSC character is lost acutely
during a RTK/Nf1/Ras-mediated expansion of glioblastic tumor
cells.
Characterization of PiggyBac Tumor Propagating Cells
Three Hras+ and three Erbb2+ tumors from different animals
were dissociated and fluorescently sorted to give pure EGFP+
populations (Figure 5A). The Hras tumor cell lines all highly ex-
pressed PDGFRA and SOX10 (at least 80%), though one Hras
cell line had significantly less PDGFRA+, SOX10+ cells (Figures
5B–5D). This PDGFRA/SOX10 co-expression was not seen in
‘‘sibling’’, control cells that were isolated from EGFP-expressing,
PBASE-transduced animals (Figure 5B).
RNA isolated from the six Hras-G12V and Erbb2V664E cell
lines and control NSCswas analyzed bymicroarray. Single-sam-
ple gene set analysis (GSEA) of cell lines using the brain tran-Figure 5. Isolation and Microarray Analysis of Highly Pure Populations
(A–C) Dissociated cells from the SVZ EP-ed withHras, but not control EGFP, expre
25 mm for B and C).
(D) Quantification of SOX10+ and PDGFRA+ cells in control NSC line and three d
(E) Transcriptome comparison of cultured tumor progenitors and NSC populatio
(F) Classification of cell lines according to the four subtypes of human glioblasto
single sample Gene Set Enrichment Analysis (ssGSEA) method.scriptome database (Cahoy et al., 2008) and the glioma subtype
signatures (Verhaak et al., 2010) revealed that the tumor cell lines
were highly heterogeneous when viewed as individual lines (Fig-
ure 5E). Erbb2-1, Erbb2-2, and Hras-1 were enriched for oligo-
dendroglial signature, while Erbb2-3, Hras-2, and Hras-3 had a
more astroglial profile (Figure 5E). These three oligodendroglial
lines were found to contain more proneural/neural signatures,
whereas the three astroglial lines were more mesenchymal
(Figure 5F).
Given that the Hras lines and Erbb2 lines were derived from
same birthdate animals (i.e., EP-ed during the same surgery)
from the same respective DNA mixes (i.e., containing either
Hras or Erbb2 for the respective groups), we suspected that
the divergence of expression profiles within tumor evolution in
each group might be partially attributed to the stochastic acqui-
sition of secondary mutations, which is suggested by several
recent studies reporting that gliomas exhibit high intratumoral
heterogeneity (Patel et al., 2014; Sottoriva et al., 2013). In
screening several tumor suppressors, we observed that all
tumors harbored at least one secondary mutation in Trp53,
p16, or p19, indicating a potential mechanism for their heteroge-
neity (Figure S6A). Several of these Trp53 mutations (A135V,
V170M, and V213M) have also been observed in other mouse
models of glioma or in human glioma (Schwartzentruber et al.,
2012; Song et al., 2013).
To confirm that EGFP+ cells are truly tumorigenic, we per-
formed transplantation of 100,000 tumors cells into naive post-
natal day (P)2 mice and saw invasive tumors similar to the initial
primary tumors marked by high SOX10 and OLIG2 expressions
(Figures S6B–S6D).
Etv5 Is Required for Ras-Mediated Gliomagenesis
Recently, Etv5 has been reported to be critical for perinatal
gliogenesis (Li et al., 2012). A preliminary microarray screen
showed that many members of the Ets transcription factor
family, and Pea3 subfamilies of the Ets family, were upregu-
lated in the tumor cells when compared with NSCs (except
Etv2, which does not appear to be expressed in the brain;
Figures 6A, 6B, and S7A). The upregulation of the Ets family
was confirmed by real-time quantitative (q)RT-PCR across
Kras, Hras, and Erbb tumors (Figure 6B). Using a well-
characterized ETV1 (aka ER81) antibody that efficiently labels
deep-layer cortical neurons (A.A.A., data not shown), we
observed the upregulation of ETV1 protein in tumor cells (Fig-
ures 6C–6C2).
Because of the pleiotropic function of Ets factors in the
brain, and due to the fact that so many members of the
Ets family were simultaneously upregulated, it would be diffi-
cult to use shRNA or floxed mice to assess Ets function in
tumorigenesis. Thus, we engineered a dominant-negativeof Tumor Cells
ss PDGFRA and SOX10. The error bars show ± SEM (The scale bar represents
ifferent Hras G12V cell lines.
ns.
ma multiforme (GBMs) defined by The Cancer Genome Atlas (TCGA) with the
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Figure 6. Ets Family Transcription Factors
Are Upregulated in Glioma and Regulate
Tumor Cell Phenotypes
(A) Increased Ets family mRNA expression in tumor
cells by microarray.
(B) Real-time qRT-PCR confirmation of microarray
data.
(C–C2) Nuclear ETV1 (aka ER81) expression in
cortical EGFP+ tumor cells.
(D and E) Plasmid schematics for bicistronic
expression of DN-Etv5 and EGFP-Hras along with
control containing TagBFP2-3XFLAG-nls. Note
that the P2A element ensures that all EGFP-Hras
G12V cells will express upstream protein so that
tumor cells cannot escape DN-Etv5.
(F and G) Coronal sections of Hras+3XFLAG (F)
and Hras+DN-Etv5 (G) brains at 6 days post-EP.
(The scale bars represent 50 mm for A–C).
(H–J) Comparison of KI67+, OLIG2, and RGs in
Hras and Hras+DN-Etv5 brains. The error bars
show ± SEM; n = 3 mice (*p < 0.05, **p < 0.01, and
paired t test).Etv5 (DN-Etv5), which consists of TagBFP2 fused to the DNA
binding domain of Etv5. DN-Etv5 cross-reacts with other
members of the Ets family to suppress their transcriptional ac-
tivities by binding the GGA(A/T) consensus site (Hasegawa266 Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authorset al., 2004). Initial attempts at co-EP
of Hras G12V and DN-Etv5 indicated
that cells expressing DN-Etv5 did not
transform at a high rate, but escaping
Hras-G12V cells quickly out-competed
DN-Etv5+ populations (R.L., data not
shown). We then constructed a bicis-
tronic plasmid containing EGFP-Hras
G12V and TagBFP2-DN-Etv5 separated
by a P2A element (Figure 6D). We
substituted the Etv5 DNA binding
domain with three FLAG epitopes and
a nuclear localization sequence (nls) to
construct the control plasmid (Fig-
ure 6E). A constitutively active Etv5-
DBD-VP64 and a full-length TagBFP5-
Etv5 were also generated (Figure S7B).
Proper function of the P2A element
was confirmed by the appropriate mem-
brane localization of Hras and nuclear
localization of TagBFP2-DN-Etv5 (Figure
S7C). Furthermore, a SRE-driven dual
luciferase assay validated that Hras
G12V activity in the P2A-containing
plasmid was equivalent to co-expressed
Hras G12V (Figure S7D). Moreover, co-
expression of these plasmids with
Pea3-driven luciferase plasmid revealed
that Hras upregulated Pea3 luciferase
activity and that co-expressed DN-Etv5
(i.e., Hras and DN-Etv5 in separate
plasmids) or bicistronic Hras/DN-Etv5efficiently reduces this increase (Figure S7E). Further, Pea3-
driven luciferase activity was increased by Etv5 over-
expression or more markedly by Etv5-VP64 expression
(Figure S7E).
Figure 7. Ets Inhibition Blocks Tumor Formation and Prevents Morbidity in Hras G12V Mice
(A and B) Hemisphere images of Hras and Hras+DN-Etv5 brains.
(C) 8-month long survival analysis indicates DN-Etv5 addition prevents morbidity (also compare with survival of animals in Figure 2G).
(D) Eight months post-EP, DN-Etv5+EGFP-Hras G12V animals did not indicate any tumor presence.
Cells did not express Sox10 or Olig2 (E–E2; the arrowheads denote EGFP
-/SOX10+/OLIG2+ cells), but did express the astrocytic markers ALDOC and ALDH1L1
(F–F2; the red arrow denotes weakly Aldoc
+/Aldh1l1+/EGFP+ cell, whereas the white arrows mark triple positive cells).Although bicistronic TagBFP-3XFLAG-nls/Hras G12V rapidly
generated proliferative hyperplasias, EP of bicistronic DN-Etv5/
Hras G12V resulted in an EGFP+ population that resembled the
normal, control EGFP EP-ed brains and failed to generate
tumors (Figures 6F and 6G). There was no evidence of gross
hyperproliferation, RGdepletion, or the increase in KI67+ prolifer-
ating cells or OLIG2+ cells in the DN-Etv5-containing group (Fig-
ures 6H–6J).
At 3 weeks post-EP, DN-Etv5 animals had no hyperplasia and
no tumor, which contrasted with the 3FLAG-bearing littermates
(Figures 7A and 7B). The overall number of cells in DN-Etv5
mice was still comparable to those seen in six month controls
(e.g., Figure 1I). DN-Etv5 animals survivedwell beyond 8months,
whereas the control group (TagBFP2-3FLAG-nls-P2A-Hras) died
(Figure 7C).
The presence of large cohorts of EGFP+ cells in these long-lived
DN-Etv5micearguesagainstnon-specificcytotoxicity (Figure7D).
Histology of these animals did not yield evidence of tumor, but
we did observe numerous hypertrophic astroglia akin to those
seen in episomal Hras G12V animals (J.J.B., data not shown).
These hypertrophic glia did not express SOX10 or OLIG2, but
instead expressed astrocyte markers ALDOC and ALDH1L1 and
had an astrocyte-like morphology (Figures 7E–7F2).DISCUSSION
We combined postnatal EP with piggyBac transposition to
model glioma by generating somatic transgenic mutants.
Through the ability to rapidly model several glioma driver muta-
tions, we identified that Ras pathway glioma requires Ets family
transcription factor activity in order to transform mutation-
harboring VZ populations into de facto tumors.
Using our modeling technology with defined temporal and
spatial transgene expression, we demonstrate that somatic
Ras hyperactivating mutations (i.e., Ras mutations, RTK muta-
tions, or Nf1 loss-of-function [LOF] manipulations) in VZ pop-
ulations cause a rapid (<6 days) depletion of NSCs and a
massive expansion of glial progenitors. Such phenomena
would be difficult to observe in traditional mouse models. For
example, tamoxifen-induced recombination in genetically engi-
neeredmousemodels happens over days in an organ-wide pop-
ulation of cells and often requires multiple, staggered injections,
complicating the ability to identify the very first cells that might
rapidly undergo transformations. Nevertheless, additional stu-
dies in our model will be necessary to rigorously lineage trace
these diverse VZ populations to see which of the initial popula-
tions (i.e., RG, ASCL1+, and/or OLIG2+) will eventually contributeCell Reports 12, 258–271, July 14, 2015 ª2015 The Authors 267
to the tumor bulk and, therefore, whether the depletion of RG is
directly tied to progenitor expansion.
The molecular mechanisms of the perinatal switch from
neurogenesis to gliogenesis have been an active area of
investigation over the past decade (Rowitch and Kriegstein,
2010). This field of inquiry has great importance due to
the underlying glial nature of tumor propagating cells. Nf1
ablation was shown to promote proliferation of immature
astroglial progenitors (Dasgupta and Gutmann, 2005), while
diminishing neuronal differentiation (Hegedus et al., 2007).
Furthermore, alterations in neurosphere behavior have been
observed in conditional Nf1 knockouts in a region-dependent
manner (Lee et al., 2010, 2012). Interestingly, extracellular
signal-regulated kinases (ERK) inhibition is able to rescue
cell fate specification in Nf1 inactivated mice by preventing
transit-amplifying progenitor cell expression of OLIG2 (Wang
et al., 2012). Of particular note, it was recently reported that
Mek activity is critical in regulating the neuron/glia fate switch
in cortical progenitors, as these knockouts demonstrated
markedly diminished gliogenesis (Li et al., 2012). Our findings
further extend these previous findings by demonstrating Nf1/
Ras function in NSCs to regulate their maintenance. Specif-
ically, Ras hyperactivity due to direct mutation, Pdgfra or
Erbb2 mutation, or through Nf1 knockdown or knockout, all
result in RG depletion. However, unlike Nf1 mutations, direct
Ras mutations are very rarely observed in glioma (Brennan
et al., 2013), so it will be important to employ other mutations
and/or combinations of mutations to see if these results can
be generalized.
During the developmental gliogenic switch, Etv5 is the only
member of the entire Ets family to be notably (>2-fold) down-
regulated in the Mek1/2-ablated brains (Li et al., 2012). How-
ever, we found that seven members of the Ets family are
upregulated in our RTK or Ras-driven tumors. By employing
a DN-Etv5, we note that the premature depletion of NSCs
and glial hyperproliferation can be blocked downstream of
Ras hyperactivity. Nevertheless, it is clear that Nf1 additionally
functions in the transit-amplifying population (Wang et al.,
2012). Given that RG and progenitor populations are simulta-
neously EP-ed, it would follow that DN-Etv5 is sufficient to
block the downstream effects of Ras hyperactivity indepen-
dently in both of these contexts (i.e., rescuing RG and prevent-
ing progenitor hyperproliferation). Interestingly, persisting glia
resemble the hypertrophic astrocytes and not the OPC-like
tumor cells, suggesting that heightened Ets transcriptional
activity is necessary for the OPC tumor propagating cell
character.
Given the heterogeneity of driver mutations in glioma, it will be
interesting to determine whether Ets family transcription factors
are a common underlying transcriptional element in glioma or
whether other signaling mechanisms are utilized by upstream
drivers. Notably, we have found that there is tumor divergence
even with the identical treatment of littermates (Figures 5D–5F).
Specifically, Hras EP-ed (or Erbb2 EP-ed) littermates of the
same age injected on the same day with the same DNA can yield
progenitors falling into disparate glioma subtypes (proneural
versus mesenchymal; Figure 5F) with different high grade patho-
logical classifications (e.g., anaplastic oligodendroglioma versus268 Cell Reports 12, 258–271, July 14, 2015 ª2015 The Authorsglioblastoma multiforme). Such findings concur with recent find-
ings on tumor diversity in in utero EP models (Chen et al., 2014)
and also with data from viral models suggesting that non-GCIMP
tumor types evolve from a common proneural subtype (Ozawa
et al., 2014). These findings in model systems are reinforced by
the emerging findings regarding patient tumor heterogeneity (Pa-
tel et al., 2014; Sottoriva et al., 2010, 2013). However, despite the
heterogeneity we saw in small groups of animals, dominant-
negative inhibition of Ets signaling was able to completely rescue
survival in much larger groups of animals, suggesting that Ets
signaling may represent a potential choke point for tumor forma-
tion. Furthermore, it will be important to determine whether
particular Ets family members are necessary for gliomagenesis
or if these factors are functionally redundant. Moreover, we
cannot assume that cell type properties are maintained during
tumorigenesis, as certain cell characteristics can be re-acquired
during tumorigenesis and subsequent de-differentiation (Vis-
vader, 2011). Specifically, there may be tumor subpopulations
that evolve Ets-independent tumor propagating capacities.
Our results indicate that hyperactivation of the Ras pathway
drives depletion of NSCs and the expansion of progenitors into
glial tumor propagating cells. Further, we have identified Ets fam-
ily signaling as a necessary downstream factor of Nf1/Ras that
mediates tumor propagating cell production. These results may
yield insight into previous findings regarding the tumor cell of
origin in gliomas being NSCs (Alcantara Llaguno et al., 2009;
Kwon et al., 2008; Wang et al., 2009; Zhu et al., 2005) or OPCs
(Assanah et al., 2006; Lei et al., 2011; Liu et al., 2011; Persson
et al., 2010; Sugiarto et al., 2011) given the intrinsic hierarchy of
stem and progenitor lineages. Rigorous lineage tracing is still
necessary to determine if the putative cell(s) of origin represent
true differences in tumor subtypes or if these disparities are due
to methodological differences that can be reconciled. Neverthe-
less, theseEts transcription factors and the resulting downstream
signaling may present new clinical targets for combating glioma.
EXPERIMENTAL PROCEDURES
Mice and EP
CD1 mice were used for most experiments, the exception being Nf1fl/fl-
related experiments, which were performed according to the Cedars-Sinai
Institutional Animal Care and Use Committee. Postnatal lateral ventricle
EPs were performed as previously described (Breunig et al., 2012). In brief,
P1–2 pups were placed on ice for 8 min until unresponsive to tail pressure.
There was 1.2 ml of a plasmid DNA mix (typically 1.0 mg/ml) in Tris-EDTA
buffer that was injected into the left lateral ventricle. Plasmid details are
available in Table S1. Employing Signagel, platinum Tweezertrodes were
used to EP with three to five pulses of 115–135 V (50 ms; separated
by 950 ms) generated with the ECM 830 BTX Electroporator (Harvard
Apparatus).
Tissue Preparation
After anesthesia, mouse brains were isolated and immersion fixed in 4% ice-
cold paraformaldehyde (PFA) overnight. Brains were then embedded in low
melting point 4% agarose and sectioned at 70 mm on a vibratome. Details
can be found in the Supplemental Information.
Immunohistochemistry
Immunohistochemistry was performed using standard methodology (Breunig
et al., 2012). Details about antibodies can be found in the Supplemental Infor-
mation and Table S2.
Imaging
Confocal images were collected on a Nikon A1R or C2 laser confocal micro-
scope. For hemi or whole brain section images, the automated stitching func-
tion of Nikon Elements was used to create a seamless merged image from
multiple image fields. Additional details can be found in the Supplemental
Information.
Quantification
Sampling for quantification was based on the scheme described in the Supple-
mental Information.
Purification of EGFP+ Tumor Cells
EGFP+ wild-type (WT) NSCs (pooled from >4 animals) or EGFP+ tumor cells
from a single tumor-bearing animal were first microdissected from the left
hemisphere, digested in accutase, and grown as monolayers according to
our previously described methods (Breunig et al., 2007). After growing to
confluence, cells underwent fluorescence-activated cell sorting (FACS) for
EGFP autofluorescence and were cultured as self-renewing monolayers.
Further details can be found in the Supplemental Information.
RNA Isolation, Microarray, and Gene Expression Analysis
RNA from EGFP+ NSCs and EGFP+ tumor cells was isolated using RNeasy+
Kits according to manufacturer’s protocols and hybridized to Affymetrix
Mouse Gene 1.0 ST microarrays. Neural cell type classification and ssGSEA
were performed as previously described (Galvao et al., 2014; Liu et al.,
2011; Verhaak et al., 2010).
ACCESSION NUMBERS
Array data have been deposited in NCBI GEO and are available under acces-
sion number GEO: GSE69254.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.06.012.
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